- OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.
- This collaboration will give OSE the opportunity to further develop its digital tools and infrastructures, particularly in terms of Artificial Intelligence and algorithmic approaches applied to the development of innovative first-in-class immunotherapies.
NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups. This program was launched during the 6th edition of “Viva Technology”, the most important Startup and Tech event organized in Europe being held in Paris from June 15-18, 2022.
Microsoft France’s « Biotech Scaler Program » aims to support companies at the crossroads of research and technology to accelerate products’ discovery and development. This program provides the selected startups with technical support in order to develop a technical framework of architecture securing scalability and startups’ data security. It also proposes a business support from Microsoft France and its partners through an ecosystem approach connecting startups, the research community, investment funds and the various health players.
Nicolas Poirier, Chief Scientific Officer of OSE…
